Pipeline
We are harnessing the biology of human aging to develop new therapies for cardiometabolic diseases
We are harnessing the biology of human aging to develop new therapies for cardiometabolic diseases
Program
Mechanism of Action
Target dosing
Indication
Status
BGE-102
NLRP3 inhibitor
(CNS penetrant)
(CNS penetrant)
Oral QD
Chronic inflammation
Diabetic macular edema
Discovery
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Discovery
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
APJ
Oral
Oral
APJ
Parenteral
Parenteral
APJ agonist
Oral QD
SQ QW
Obesity
Discovery
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Discovery
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Program 1
Program 2
Target discovery
Undisclosed
Undisclosed
Multiple targets
-
-
-
Cardiometabolic (various)
Cardiometabolic (various)
-
Discovery
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Discovery
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Discovery
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3